In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens

Abstract Background Systemic Escherichia coli infections cause early mortality of commercial broiler chickens. Although enrofloxacin has long been used in poultry, the in vivo pharmacokinetic/pharmacodynamic (PK/PD) relationship of enrofloxacin against E. coli is unclear. The present study aimed to...

Full description

Bibliographic Details
Main Authors: Xia Xiao, Lijie Jiang, Weixuan Lan, Yongjia Jiang, Zhiqiang Wang
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Veterinary Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12917-018-1698-3
_version_ 1819078018286485504
author Xia Xiao
Lijie Jiang
Weixuan Lan
Yongjia Jiang
Zhiqiang Wang
author_facet Xia Xiao
Lijie Jiang
Weixuan Lan
Yongjia Jiang
Zhiqiang Wang
author_sort Xia Xiao
collection DOAJ
description Abstract Background Systemic Escherichia coli infections cause early mortality of commercial broiler chickens. Although enrofloxacin has long been used in poultry, the in vivo pharmacokinetic/pharmacodynamic (PK/PD) relationship of enrofloxacin against E. coli is unclear. The present study aimed to establish an in vivo PK/PD model of enrofloxacin against E. coli in seven-day-old chicks and to ascertain whether the selection of target organ for PD determination is critical for parameter magnitude calculation in enrofloxacin PK/PD modeling. Results The in vivo effectiveness of enrofloxacin against E. coli in different organs varied, with the E max ranging from − 4.4 to − 5.8 Log10 colony forming units (cfu)/mL or cfu/g. Both the surrogate AUC0–24/MIC of enrofloxacin or AUC0–24/MIC of the combination of enrofloxacin and ciprofloxacin correlated well with effectiveness in each organ. The AUC0–24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively. Conclusions The in vivo effectiveness of enrofloxacin against E. coli in different organs was not identical after administration of the same dosage. To describe the magnitude of PK/PD parameter exactly, bacterial loading reduction in different organs as PD endpoints should be evaluated and compared in PK/PD modeling. The selection of a target organ to evaluate PDs is critical for rational dosage recommendation.
first_indexed 2024-12-21T19:06:25Z
format Article
id doaj.art-59bda71786f94dc3a33932be12b74597
institution Directory Open Access Journal
issn 1746-6148
language English
last_indexed 2024-12-21T19:06:25Z
publishDate 2018-11-01
publisher BMC
record_format Article
series BMC Veterinary Research
spelling doaj.art-59bda71786f94dc3a33932be12b745972022-12-21T18:53:20ZengBMCBMC Veterinary Research1746-61482018-11-011411910.1186/s12917-018-1698-3In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickensXia Xiao0Lijie Jiang1Weixuan Lan2Yongjia Jiang3Zhiqiang Wang4College of Veterinary Medicine, Yangzhou UniversityCollege of Veterinary Medicine, Yangzhou UniversityCollege of Veterinary Medicine, Yangzhou UniversityCollege of Veterinary Medicine, Yangzhou UniversityCollege of Veterinary Medicine, Yangzhou UniversityAbstract Background Systemic Escherichia coli infections cause early mortality of commercial broiler chickens. Although enrofloxacin has long been used in poultry, the in vivo pharmacokinetic/pharmacodynamic (PK/PD) relationship of enrofloxacin against E. coli is unclear. The present study aimed to establish an in vivo PK/PD model of enrofloxacin against E. coli in seven-day-old chicks and to ascertain whether the selection of target organ for PD determination is critical for parameter magnitude calculation in enrofloxacin PK/PD modeling. Results The in vivo effectiveness of enrofloxacin against E. coli in different organs varied, with the E max ranging from − 4.4 to − 5.8 Log10 colony forming units (cfu)/mL or cfu/g. Both the surrogate AUC0–24/MIC of enrofloxacin or AUC0–24/MIC of the combination of enrofloxacin and ciprofloxacin correlated well with effectiveness in each organ. The AUC0–24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively. Conclusions The in vivo effectiveness of enrofloxacin against E. coli in different organs was not identical after administration of the same dosage. To describe the magnitude of PK/PD parameter exactly, bacterial loading reduction in different organs as PD endpoints should be evaluated and compared in PK/PD modeling. The selection of a target organ to evaluate PDs is critical for rational dosage recommendation.http://link.springer.com/article/10.1186/s12917-018-1698-3Escherichia coliEnrofloxacinIn vivoPK/PD modelingChicken
spellingShingle Xia Xiao
Lijie Jiang
Weixuan Lan
Yongjia Jiang
Zhiqiang Wang
In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
BMC Veterinary Research
Escherichia coli
Enrofloxacin
In vivo
PK/PD modeling
Chicken
title In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
title_full In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
title_fullStr In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
title_full_unstemmed In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
title_short In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
title_sort in vivo pharmacokinetic pharmacodynamic modeling of enrofloxacin against escherichia coli in broiler chickens
topic Escherichia coli
Enrofloxacin
In vivo
PK/PD modeling
Chicken
url http://link.springer.com/article/10.1186/s12917-018-1698-3
work_keys_str_mv AT xiaxiao invivopharmacokineticpharmacodynamicmodelingofenrofloxacinagainstescherichiacoliinbroilerchickens
AT lijiejiang invivopharmacokineticpharmacodynamicmodelingofenrofloxacinagainstescherichiacoliinbroilerchickens
AT weixuanlan invivopharmacokineticpharmacodynamicmodelingofenrofloxacinagainstescherichiacoliinbroilerchickens
AT yongjiajiang invivopharmacokineticpharmacodynamicmodelingofenrofloxacinagainstescherichiacoliinbroilerchickens
AT zhiqiangwang invivopharmacokineticpharmacodynamicmodelingofenrofloxacinagainstescherichiacoliinbroilerchickens